Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use.
暂无分享,去创建一个
E. Alp | A. Ulu-Kilic | H. Demiraslan | D. Altun | F. Cevahir | G. Kalin
[1] Roopali Sharma,et al. The role of tigecycline in the treatment of infections in light of the new black box warning , 2014, Expert review of anti-infective therapy.
[2] R. Nir-Paz,et al. Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] M. Falagas,et al. Effectiveness and safety of tigecycline: focus on use for approved indications. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] E. García-Cabrera,et al. More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates. , 2012, The Journal of antimicrobial chemotherapy.
[5] L. Leibovici,et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. , 2011, The Journal of antimicrobial chemotherapy.
[6] P. Astagneau,et al. Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France. , 2011, The Journal of hospital infection.
[7] E. Cordero,et al. Superinfection during treatment of nosocomial infections with tigecycline , 2010, European Journal of Clinical Microbiology & Infectious Diseases.
[8] Yehuda Carmeli,et al. Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact , 2006, Antimicrobial Agents and Chemotherapy.
[9] E. Loh,et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744] , 2005, BMC infectious diseases.
[10] E. Loh,et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. , 2005, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[11] J. Timsit,et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Leonard Leibovici,et al. Risk factors and a clinical index for diagnosis of Pseudomonas aeruginosa bacteremia. , 1995, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[13] B. Yangco,et al. CDC definitions for nosocomial infections. , 1989, American journal of infection control.
[14] J M Hughes,et al. CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.